Sheffield University experts expand Covid-19 vaccine trial to include over 55s

Experts at the University of Sheffield have expanded a Covid-19 vaccine trial to include people aged over 55-years-old.
Watch more of our videos on Shots! 
and live on Freeview channel 276
Visit Shots! now

Researchers from the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust are looking to recruit 200 healthy volunteers between 56 and 70 and over 70-years-old in the major coronavirus vaccine trial.

It comes as the national study enters its next phase and seeks to assess how a potential new vaccine could protect people against the virus in different age groups.

Hide Ad
Hide Ad

The team which are seeking volunteers in the Sheffield postcode area, hope to recruit 100 people in each age bracket in the trial which has already enrolled health volunteers aged between 18 and 55.

Researches from the University of Sheffield are looking to recruit healthy volunteers aged over 55 in Covid-19 vaccine trial.Researches from the University of Sheffield are looking to recruit healthy volunteers aged over 55 in Covid-19 vaccine trial.
Researches from the University of Sheffield are looking to recruit healthy volunteers aged over 55 in Covid-19 vaccine trial.

Out of 1,077 adult volunteers, the vaccine has produced both neutralising antibodies and an effective T-cell response when given to people from the ages of 18 and 55.

Director of Research and Development at Sheffield Teaching Hospitals NHS Foundation Trust Professor Simon Heller said: “The Oxford vaccine trial is assessing how well people across a broad range of ages could be protected from COVID-19 from this new vaccine called ChAdOx1 nCoV-19.

"We are delighted to be expanding the study to include people aged between 56 and 70 and those over 70, and we urge anyone in these age groups who is interested and lives in the Sheffield postcode area to visit the trial website to find out more about what’s involved.”

Hide Ad
Hide Ad

Trial participants will be randomised to receive two doses of either the ChAdOx1 nCoV-19 or a licensed meningitis vaccine (MenACWY) which will be used as a comparison.

Those taking part in the study will only find out if they received the ChAdOx1 nCoV-19 vaccine at the end of the trial to ensure there is no bias during the trial.

Sheffield is one of 18 sites across the UK taking part in the major national study, with 12,330 participants due to take part.

The city’s trial is being run in partnership with the University of Sheffield, health and social care organisations, alongside education and transport sectors across the city – with support from the Sheffield National Institute for Health Research’s Clinical Research Facility.

Editor's message: Thank you for reading this story. The dramatic events of 2020 are having a major impact on our advertisers and thus our revenues. The Star is more reliant than ever on you taking out a digital subscription to support our journalism. You can subscribe here for unlimited access to Sheffield news and information online. Every subscription helps us continue providing trusted, local journalism and campaign on your behalf for our city.

Related topics: